US FDA fast-tracks MedImmune's RSV candidate

9 April 2015

MedImmune, the global biologics R&D unit of Anglo-Swedish pharma major AstraZeneca (LSE: AZN), has received fast track designation from the US Food and Drug Administration for the development of MEDI8897.

This high-potency, extended half-life monoclonal antibody (MAb) is being investigated for the prevention of lower respiratory tract illness (LRTI) caused by respiratory syncytial virus (RSV) in infants and young children. The FDA’s fast track program is designed to expedite the development and review of drugs that treat serious conditions and fill an unmet medical need.

MedImmune previously discovered, developed and currently markets a monoclonal antibody for severe RSV disease. The company aims to increase the number of infants who are protected from LRTI caused by RSV through its development of MEDI8897 for the passive immunization of all infants, term and preterm. As part of its development program, MedImmune is applying its proprietary technology to increase the half-life of MEDI8897, so that only one dose will be needed for the entire RSV season.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK